648 related articles for article (PubMed ID: 27575488)
21. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol.
Peyron R; Aubény E; Targosz V; Silvestre L; Renault M; Elkik F; Leclerc P; Ulmann A; Baulieu EE
N Engl J Med; 1993 May; 328(21):1509-13. PubMed ID: 8479487
[TBL] [Abstract][Full Text] [Related]
22. Acceptability of suction curettage and mifepristone abortion in the United States: a prospective comparison study.
Jensen JT; Harvey SM; Beckman LJ
Am J Obstet Gynecol; 2000 Jun; 182(6):1292-9. PubMed ID: 10871441
[TBL] [Abstract][Full Text] [Related]
23. Termination of pregnancy at 9-13 weeks' amenorrhoea with mifepristone and misoprostol.
Ashok PW; Flett GM; Templeton A
Lancet; 1998 Aug; 352(9127):542-3. PubMed ID: 9716062
[TBL] [Abstract][Full Text] [Related]
24. A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation.
Hamoda H; Ashok PW; Flett GM; Templeton A
BJOG; 2005 Aug; 112(8):1102-8. PubMed ID: 16045525
[TBL] [Abstract][Full Text] [Related]
25. If we can do it for misoprostol, why not for mifepristone? The case for taking mifepristone out of the office in medical abortion.
Gold M; Chong E
Contraception; 2015 Sep; 92(3):194-6. PubMed ID: 26093187
[TBL] [Abstract][Full Text] [Related]
26. Abortion: epidemiology, safety, and technique.
Blumenthal PD
Curr Opin Obstet Gynecol; 1992 Aug; 4(4):506-12. PubMed ID: 1504270
[TBL] [Abstract][Full Text] [Related]
27. Mifepristone plus vaginal misoprostol vs vaginal misoprostol alone for medical abortion in gestation 63 days or less in Nepalese women: a quasi-randomized controlled trial.
Chawdhary R; Rana A; Pradhan N
J Obstet Gynaecol Res; 2009 Feb; 35(1):78-85. PubMed ID: 19215552
[TBL] [Abstract][Full Text] [Related]
28. Introducing medication abortion into public sector facilities in KwaZulu-Natal, South Africa: an operations research study.
Blanchard K; Lince-Deroche N; Fetters T; Devjee J; de Menezes ID; Trueman K; Sudhinaraset M; Nkonko E; Moodley J
Contraception; 2015 Oct; 92(4):330-8. PubMed ID: 26162575
[TBL] [Abstract][Full Text] [Related]
29. Update on medical abortion: simplifying the process for women.
Whaley NS; Burke AE
Curr Opin Obstet Gynecol; 2015 Dec; 27(6):476-81. PubMed ID: 26418145
[TBL] [Abstract][Full Text] [Related]
30. The Safety and Efficacy of a "No Touch" Abortion Program Implemented in the Greater Toronto Area During the COVID-19 Pandemic.
Smith MK; Biderman M; Frotten E; Warden S; Dunn S; Dmytryshyn R; Thorne JG
J Obstet Gynaecol Can; 2024 Jun; 46(6):102429. PubMed ID: 38458271
[TBL] [Abstract][Full Text] [Related]
31. Acceptability and feasibility of the use of 400 μg of sublingual misoprostol after mifepristone for medical abortion up to 63 days since the last menstrual period: evidence from Uzbekistan.
Raghavan S; Tsereteli T; Kamilov A; Kurbanbekova D; Yusupov D; Kasimova F; Jymagylova D; Winikoff B
Eur J Contracept Reprod Health Care; 2013 Apr; 18(2):104-11. PubMed ID: 23387475
[TBL] [Abstract][Full Text] [Related]
32. Acceptability and feasibility of medical abortion in Nepal.
Karki C; Pokharel H; Kushwaha A; Manandhar D; Bracken H; Winikoff B
Int J Gynaecol Obstet; 2009 Jul; 106(1):39-42. PubMed ID: 19345944
[TBL] [Abstract][Full Text] [Related]
33. Medical management of early pregnancy failure (EPF): a retrospective analysis of a combined protocol of mifepristone and misoprostol used in clinical practice.
Colleselli V; Schreiber CA; D'Costa E; Mangesius S; Wildt L; Seeber BE
Arch Gynecol Obstet; 2014 Jun; 289(6):1341-5. PubMed ID: 24305748
[TBL] [Abstract][Full Text] [Related]
34. Association of Facility Type With Procedural-Related Morbidities and Adverse Events Among Patients Undergoing Induced Abortions.
Roberts SCM; Upadhyay UD; Liu G; Kerns JL; Ba D; Beam N; Leslie DL
JAMA; 2018 Jun; 319(24):2497-2506. PubMed ID: 29946727
[TBL] [Abstract][Full Text] [Related]
35. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period.
Middleton T; Schaff E; Fielding SL; Scahill M; Shannon C; Westheimer E; Wilkinson T; Winikoff B
Contraception; 2005 Nov; 72(5):328-32. PubMed ID: 16246656
[TBL] [Abstract][Full Text] [Related]
36. Are two doses of misoprostol after mifepristone for early abortion better than one?
Coyaji K; Krishna U; Ambardekar S; Bracken H; Raote V; Mandlekar A; Winikoff B
BJOG; 2007 Mar; 114(3):271-8. PubMed ID: 17217359
[TBL] [Abstract][Full Text] [Related]
37. A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation.
Hamoda H; Ashok PW; Flett GM; Templeton A
Hum Reprod; 2005 Aug; 20(8):2348-54. PubMed ID: 15878927
[TBL] [Abstract][Full Text] [Related]
38. The impact of recent changes in therapeutic abortion laws.
Kahn JB; Bourne JP; Tyler CW
Clin Obstet Gynecol; 1971 Dec; 14(4):1130-48. PubMed ID: 5146955
[TBL] [Abstract][Full Text] [Related]
39. The impact of Mississippi's mandatory delay law on the timing of abortion.
Joyce T; Kaestner R
Fam Plann Perspect; 2000; 32(1):4-13. PubMed ID: 10710701
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of self-managed medication abortion between 13 and 24 weeks gestation: A retrospective review of case records from accompaniment groups in Argentina, Chile, and Ecuador.
Moseson H; Bullard KA; Cisternas C; Grosso B; Vera V; Gerdts C
Contraception; 2020 Aug; 102(2):91-98. PubMed ID: 32360817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
